250 related articles for article (PubMed ID: 3933826)
1. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio) ethyl] mitomycin C (BMY-25067).
Bradner WT; Rose WC; Schurig JE; Florczyk AP
Invest New Drugs; 1990; 8 Suppl 1():S1-7. PubMed ID: 2380013
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
6. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
7. Experimental tumor inhibitory and toxic properties of the mitomycin A analogue 7-(2-hydroxyethoxy) mitosane (BMY-25551).
Bradner WT; Catino JJ; Long BH; Rose WC; Schurig JE
Anticancer Res; 1992; 12(3):959-64. PubMed ID: 1622154
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity comparison of mitomycin C and mitomycin A analogues (review).
Bradner WT; Remers WA; Vyas DM
Anticancer Res; 1989; 9(4):1095-9. PubMed ID: 2510580
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
10. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells.
Willson JK; Long BH; Chakrabarty S; Brattain DE; Brattain MG
Cancer Res; 1985 Nov; 45(11 Pt 1):5281-6. PubMed ID: 3931904
[TBL] [Abstract][Full Text] [Related]
11. Enhanced anticancer efficacy by use of mitomycin C adsorbed on small activated carbon particles in mice.
Hagiwara A; Takahashi T; Ueda T; Nakagawa Y
Jpn J Cancer Res; 1987 Apr; 78(4):405-8. PubMed ID: 3108220
[TBL] [Abstract][Full Text] [Related]
12. Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation.
Seymour LW; Soyez H; De Marre A; Shoaibi MA; Schacht EH
Anticancer Drug Des; 1996 Jul; 11(5):351-65. PubMed ID: 8765529
[TBL] [Abstract][Full Text] [Related]
13. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia].
Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
Gan To Kagaku Ryoho; 1991 Feb; 18(2):201-9. PubMed ID: 1899547
[TBL] [Abstract][Full Text] [Related]
14. [Recent advanced studies on mitomycins, antitumor activity and mode of action].
Taguchi T; Morimoto M
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2396-409. PubMed ID: 3111386
[TBL] [Abstract][Full Text] [Related]
15. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 7-n-(p-hydroxyphenyl)-mitomycin C in experimental tumor systems.
Imai R; Morimoto M; Marumo H; Kobayashi T; Tsuruo T; Inaba M; Tsukagoshi S; Sakurai Y
Gan; 1981 Dec; 72(6):944-9. PubMed ID: 6804296
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.
Pierré A; Kraus-Berthier L; Atassi G; Cros S; Poupon MF; Lavielle G; Berlion M; Bizzari JP
Cancer Res; 1991 May; 51(9):2312-8. PubMed ID: 2015595
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
20. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
